Stoke Therapeutics, Inc. (STOK)
30.16
+0.11
(+0.37%)
USD |
NASDAQ |
Sep 09, 09:57
Stoke Therapeutics Shareholders Equity (Quarterly) : 345.55M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 345.55M |
| March 31, 2026 | 394.88M |
| December 31, 2025 | 352.46M |
| September 30, 2025 | 308.10M |
| June 30, 2025 | 334.94M |
| March 31, 2025 | 350.07M |
| December 31, 2024 | 229.02M |
| September 30, 2024 | 232.11M |
| June 30, 2024 | 242.71M |
| March 31, 2024 | 140.34M |
| December 31, 2023 | 159.56M |
| September 30, 2023 | 173.00M |
| June 30, 2023 | 190.20M |
| March 31, 2023 | 213.82M |
| December 31, 2022 | 184.85M |
| September 30, 2022 | 204.14M |
| Date | Value |
|---|---|
| June 30, 2022 | 224.32M |
| March 31, 2022 | 239.98M |
| December 31, 2021 | 217.78M |
| September 30, 2021 | 237.51M |
| June 30, 2021 | 255.07M |
| March 31, 2021 | 272.46M |
| December 31, 2020 | 286.08M |
| September 30, 2020 | 192.54M |
| June 30, 2020 | 203.40M |
| March 31, 2020 | 214.34M |
| December 31, 2019 | 224.43M |
| September 30, 2019 | 233.68M |
| June 30, 2019 | 241.54M |
| March 31, 2019 | 99.58M |
| December 31, 2018 | 105.07M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Biogen, Inc. | 18.85B |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 393.97M |
| Total Liabilities (Quarterly) | 48.42M |
| Debt to Equity Ratio | 0.0078 |
| Current Ratio | 7.692 |
| Net Debt Paydown Yield | 0.02% |